Hong Kong's Securities and Futures Commission, the Accounting and Financial Reporting Council, and the Stock Exchange of Hong Kong have issued a joint statement addressing growing regulatory concerns over a rising number of cases in which listed issuers receive "disclaimer of opinion" audit reports solely due to going concern issues.

The regulators said they will continue to closely monitor the situation and will take appropriate regulatory, disciplinary, or enforcement action if misconduct or non-compliance is found.

If the situation does not improve significantly, the Stock Exchange will consider amending the Listing Rules as needed, including requiring a trading halt for listed issuers whose financial statements carry a disclaimer of opinion issued solely on going concern grounds.

Market Overview

Overnight on Wall Street, the Dow Jones Industrial Average rose 51.77 points, or 0.1%, to close at 51,231.64.

The S&P 500 fell 36.41 points, or 0.47%, to 7,765.36, while the Nasdaq Composite dropped 345.35 points, or 1.25%, to 27,193.34.

Most large-cap technology stocks declined, with Apple up 1.11%, Amazon down 2.25%, and Nvidia down 2.94%.

The Philadelphia Semiconductor Index fell 3.39% to 12,623.72. TSMC dropped 3.01%. Memory chip names broadly declined, with Western Digital down 2.99%, Seagate Technology down 4.05%, and SK Hynix down 4.35%. Optical communications stocks fell sharply, with Lumentum down 5.62% and Corning down 6.38%. Oil and gas stocks rose broadly, with Occidental Petroleum up 3.56%.

Consumer retail names gained broadly, with Lowe's up 4.03% and PepsiCo up 3.73%.

Most popular Chinese concept stocks declined, with the Nasdaq Golden Dragon China Index down 0.62%.

The Hang Seng Index ADR rose, implied to close at 23,977.67 points, up 191.88 points, or 0.81%, from the Hong Kong close.

On the New York Mercantile Exchange, the front-month WTI crude oil futures contract rose US$2.90 to settle at US$91.18 per barrel, a gain of 3.29%.

COMEX front-month gold futures rose US$17.60, or 0.43%, to US$4,158.3 per ounce.

Key Developments

XIN YUAN ENT (01748) received a voluntary conditional general cash offer from Ocean Vivo Limited at approximately 25.57% premium.

The company announced that on August 19, 2026, the offeror Ocean Vivo Limited notified the company of its clear intention, subject to satisfaction of preconditions, to make a voluntary conditional general cash offer through ICBC International Financing on behalf of the offeror, on the terms and subject to the conditions set out, to acquire all shares not already owned by the offeror and parties acting in concert with it.

The offer price of HK$2.21 per share represents a premium of approximately 25.57% over the closing price of HK$1.76 per share on February 20, 2025.

SUNSHINE PHARMA (06887) announced that its independently developed insulin degludec/insulin aspart injection has officially received marketing approval from China's National Medical Products Administration.

The approval covers both pen cartridges and prefilled injection pens. With this approval, the group's insulin products approved in the Chinese market have increased to seven, building a full-series insulin product matrix spanning from second-generation to fourth-generation products and covering basal, prandial, and premixed clinical application scenarios.

SBP GROUP (01177) announced that TQC3721 inhalation suspension, a PDE3/4 inhibitor, has completed enrollment of all subjects in its Phase III registration clinical trial.

As an innovative inhalation formulation, TQC3721 is being developed in two dosage forms, nebulized inhalation suspension and dry powder inhalation, to suit different patient populations, disease severity levels, and commercial application scenarios. For COPD, the TQC3721 nebulized inhalation suspension has already demonstrated best-in-class potential in Phase II studies. This dosage form has now completed Phase III clinical enrollment, while the dry powder inhalation is also advancing into Phase II clinical trials, with the potential to become China's first approved domestic inhaled PDE3/4 dual inhibitor.

PONY-W (02026) officially announced its entry into London, UK, accelerating the deployment of autonomous driving in Europe.

The autonomous driving company and global mobility platform Uber announced they are advancing the introduction of their seventh-generation Robotaxi to London and expect to begin road testing in the coming weeks. London will become another important city in the large-scale deployment strategy of Pony.ai and Uber for Robotaxi services in Europe.

FAST RETAIL-DRS (06288) released its annual results, with profit attributable to shareholders of 542.516 billion yen, up 25.3% year-on-year, and will resume trading on October 9.

Fast Retailing Co., Ltd.'s consolidated revenue for the fiscal year 2026 (September 1, 2025 to August 31, 2026) totaled 3,963.3 billion yen, up 16.6% from the prior year. Operating profit, which reflects the profit from the business itself after deducting cost of sales and selling, general and administrative expenses from total revenue, was 718.4 billion yen, up 30.4% year-on-year, recording substantial growth in both revenue and profit and marking the fifth consecutive fiscal year of record-high results.

The group's UNIQLO business achieved revenue and profit growth in every region, mainly attributable to the continued opening of high-quality stores that convey the "LifeWear" concept, while strategic reinforcement of the linkage between merchandise, store layout, and information dissemination also proved effective.

CNOOC (00883) announced that more than half of the originally planned shareholding increase period has passed, but the actual increase amount has not reached 50% of the lower limit of the planned amount range.

As of October 8, 2026, more than half of the originally planned increase period has passed, but due to various factors including overseas geopolitical issues, large fluctuations in international crude oil prices, and changes in capital markets, the actual cumulative increase amount has not reached 50% of the lower limit of the planned amount range. China National Offshore Oil Group will continue to increase its shareholding in the company at appropriate times using its own funds in accordance with the shareholding increase plan.

DONGYUE GROUP (00189) announced that Dongyue Silicon Material expects net profit attributable to shareholders of 547 million yuan to 567 million yuan for the first three quarters.

The company released a performance forecast for its non-wholly-owned subsidiary Shandong Dongyue Organosilicon Material Co., Ltd. for the first three quarters of 2026. The forecast states that Dongyue Silicon Material's net profit attributable to its shareholders for the three months ended September 30, 2026 is expected to be a profit of 547 million yuan to 567 million yuan, compared with a profit of approximately 2.857 million yuan in the same period last year. Net profit after deducting non-recurring gains and losses is expected to be a profit of 589 million yuan to 609 million yuan, compared with a profit of approximately 11.821 million yuan in the same period last year.

RIDGE OUTDOOR (02720) subsidiary plans to acquire the operating assets of UK fishing rod brand Harrison Advanced Rods.

After completion of the acquisition, the target assets will be transferred to Harrison Advanced Rods Ltd. Dr. Stephen Harrison, founder of Suremag Limited, has been appointed as a director and chief executive officer of Harrison Advanced Rods Ltd. The acquisition is in line with the group's strategy of acquiring and developing heritage brands with good reputations and loyal customer bases, and accelerating their penetration into global markets.

SIHUAN PHARM (00460) made a strategic investment in Hanteng Biotech to improve its full-industry-chain layout in regenerative medical aesthetics.

The company announced that recently, its subsidiary Meiyan Space Biotechnology (Jilin) Co., Ltd. completed a strategic equity investment in Guangzhou Hanteng Biotechnology Co., Ltd. At the same time, the two parties plan to carry out joint commercialization cooperation around the commercial sales of Hanteng Biotech's full-length triple-helix recombinant human collagen raw material. Meiyan Space will develop a series of collagen medical aesthetics products based on this raw material to improve the group's regenerative medical aesthetics business layout.

Stock Spotlight

CTIHK (06055) has appointed a new board chairman, with ample medium-to-long-term growth momentum.

Li Bin entered Guangdong Tobacco in July 1992 and has worked in China's tobacco industry for 34 years, having served as the principal head of two China Tobacco industrial companies.

Cinda Securities released a research report stating that the company's performance in the first half of 2026 contracted slightly, mainly due to the impact of US tobacco leaf imports. The bank expects the year-on-year impact to weaken in the second half of 2026. Considering downstream inventory consumption and tax reduction negotiations in China-US talks, with multiple types of tobacco leaves and tobacco products on the tax reduction list, if business returns to normal in 2027, the company's profits are expected to increase.

In addition, the bank expects cigarette exports to gradually return to normal, driving a steady rise in the company's profit center. Although short-term changes in new tobacco products are limited, if domestic policies open up, positive changes from the supply side are expected. The bank is watching the impact of extreme weather in the short term, while the company has ample growth momentum in the medium to long term.

Recently, meteorological agencies have collectively upgraded this round of El Nino to super-strong levels. The bank expects tobacco leaf production conditions in South America and Africa to affect tobacco leaf prices, at which point the company's average import and export prices, gross margin, and sales volume for tobacco leaves will all be affected. In addition, the company has clearly stated that it will grasp the development and reform opportunities of the 15th Five-Year Plan, leverage its advantages as a main entity for international market expansion and an investment and financing platform, continue to drive growth through both organic growth and external expansion, and achieve steady growth in the future.